BMGL

6-K - Basel Medical Group Ltd (0002004489) (Filer)

3 - Basel Medical Group Ltd (0002004489) (Issuer)

3 - Basel Medical Group Ltd (0002004489) (Issuer)

3 - Basel Medical Group Ltd (0002004489) (Issuer)

3 - Basel Medical Group Ltd (0002004489) (Issuer)

3 - Basel Medical Group Ltd (0002004489) (Issuer)

3 - Basel Medical Group Ltd (0002004489) (Issuer)

6-K - Basel Medical Group Ltd (0002004489) (Filer)

6-K - Basel Medical Group Ltd (0002004489) (Filer)

Singapore, March 24, 2026 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (NASDAQ:BMGL) (the "Company") today announced that it has received notification from Nasdaq that based on the Company's amended annual report on Form 20-F for the fiscal year of 2025, which was filed with the SEC on March 13, 2026, Nasdaq Staff has now determined that the Company has complied with the periodic filing requirement for The Nasdaq Stock Market under Listing Rule 5250(c)(1) (the "Periodic Filing Rule"). Accordingly, the prior deficiency relating to the Periodic Filing Rule has now been resolved. About Basel Medical Group Ltd Basel Medical is a Singapore-based provider of orthopedic and trauma services, spor

20-F/A - Basel Medical Group Ltd (0002004489) (Filer)

3 - Basel Medical Group Ltd (0002004489) (Issuer)

6-K - Basel Medical Group Ltd (0002004489) (Filer)

Singapore, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (NASDAQ:BMGL) (the "Company"), today announced that it has received notification from Nasdaq that based on the closing bid price of the Company's shares for the last 30 consecutive business days, the Company no longer meets the requirements under Nasdaq's Listing Rules (the "Rules") for listed securities to maintain a minimum bid price of $1 per share. The Rules provide the Company a compliance period of 180 calendar days in which to regain compliance. If at any time during this 180 day period the closing bid price of the Company's security is at least $1 for a minimum of ten consecutive business days, Nasdaq will provid

6-K - Basel Medical Group Ltd (0002004489) (Filer)

6-K - Basel Medical Group Ltd (0002004489) (Filer)

Singapore, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (NASDAQ:BMGL) (the "Company"), today announced that it has received notification from Nasdaq that the Company's annual report on Form 20-F for the fiscal year ended June 30, 2025 was incomplete and that the Company is delinquent in its filing obligations. This was because such report failed to include an opinion from the Company's auditor, NLA DFK Assurance PAC, on the Company's financial statements. Pursuant to Listing Rule 5250(c)(1), companies shall timely file all required periodic financial reports with the United States Securities and Exchange Commission, and annual reports filed shall contain audited financial stat

NT 20-F - Basel Medical Group Ltd (0002004489) (Filer)

6-K - Basel Medical Group Ltd (0002004489) (Filer)

6-K - Basel Medical Group Ltd (0002004489) (Filer)

6-K - Basel Medical Group Ltd (0002004489) (Filer)

Singapore, July 17, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (NASDAQ:BMGL), today announced that it is putting on hold on the acquisition of BTC digital asset. After thorough discussions, Basel and the consortium of Bitcoin (BTC) holders have mutually agreed to pause the acquisition of digital asset. This decision reflects the ongoing regulatory review of digital assets by US authorities and the current lack of clarity on how forthcoming policies may impact the transaction. Given these uncertainties, both parties believe it is prudent to defer the deal until there is greater regulatory certainty. We will continue to monitor developments closely and reassess the opportunity once th

6-K - Basel Medical Group Ltd (0002004489) (Filer)

6-K - Basel Medical Group Ltd (0002004489) (Filer)

Singapore, June 26, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (NASDAQ:BMGL) (the "Company"), today announced that Cathay Securities, Inc., as the representative of the several underwriters of the Company's initial public offering, has granted its consent on June 23, 2025 to the lock-up provision in the underwriting agreement dated February 24, 2025, permitting (i) a public offering or private placement of new securities of the Company, and (ii) the filing with the U.S. Securities and Exchange Commission of a registration statement under the Securities Act of 1933 in relation to such offering or placement, prior to the expiration of the lock-up period which was due to expire six mont